文献速递肿瘤 PET/CT

18F-PSMA-1007 PET/CT在251例前列腺癌根治术后生化复发患者中的检测效能

Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
PubMed 文献 · J Nucl Med · 2018-07-24

本研究回顾性分析了3个学术中心251例前列腺癌根治术后生化复发患者,评估18F-PSMA-1007 PET/CT的检测效能,结果显示204例(81.3%)发现复发灶,检出率随PSA水平升高而增加。

要点

  • 18F-PSMA-1007 PET/CT在生化复发患者中总检出率为81.3%(204/251)。
  • PSA≥2 ng/mL组检出率94.0%,0.2≤PSA<0.5 ng/mL组为61.5%。
  • 影像前6个月内接受ADT者检出率更高(91.7% vs 78.0%,P=0.0179)。

核心结论

  • 18F-PSMA-1007 PET/CT对前列腺癌根治术后生化复发具有高检出率,与已发表的68Ga标记PSMA配体相当或更优。

研究设计与样本

  • 回顾性分析纳入来自3个学术中心的251例前列腺癌根治术后生化复发患者。
  • 排除接受过二线雄激素剥夺治疗或化疗的患者,允许既往一线ADT暴露。
  • 中位PSA水平为1.2 ng/mL(范围0.2-228 ng/mL)。
  • 所有患者在注射301±46 MBq 18F-PSMA-1007后92±26分钟行PSMA PET/CT。

主要发现

  • 251例中204例(81.3%)在18F-PSMA-1007 PET/CT上发现复发证据。
  • PSA≥2、1≤PSA<2、0.5≤PSA<1、0.2≤PSA<0.5 ng/mL组的检出率分别为94.0%(79/84)、90.9%(50/55)、74.5%(35/47)、61.5%(40/65)。
  • 局部复发占24.7%(n=62),盆腔淋巴结转移占40.6%(n=102),腹膜后淋巴结转移占19.5%(n=49),膈上转移占12.0%(n=30),骨转移占40.2%(n=101),内脏转移占3.6%(n=9)。
  • Gleason评分≤7 vs ≥8组检出率趋势更高(76.3% vs 86.7%),但无统计学显著差异(P=0.32)。
  • 影像前6个月内接受过ADT者检出率更高(91.7% vs 78.0%,P=0.0179)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA)-targeted PET imaging recently emerged as a new method for the staging and restaging of prostate cancer. Most published studies investigated the diagnostic potential of 68Ga-labeled PSMA agents that are excreted renally. 18F-PSMA-1007 is a novel PSMA ligand that has excellent preclinical characteristics and that is only minimally excreted by the urinary tract, a potential advantage for pelvic imaging. The aim of this study was to investigate the diagnostic efficacy of 18F-PSMA-1007 for biochemical recurrence (BCR) after radical prostatectomy. Methods: From 3 academic centers, 251 patients with BCR after radical prostatectomy were evaluated in a retrospective analysis. Patients who had received second-line androgen deprivation therapy (ADT) or chemotherapy were excluded, but prior first-line ADT exposure was allowed. The median prostate-specific antigen (PSA) level was 1.2 ng/mL (range, 0.2-228 ng/mL). All patients underwent PSMA PET/CT at 92 ± 26 min after injection of 301 ± 46 MBq of 18F-PSMA-1007. The rate of detection of presumed recurrence sites was correlated with the PSA level and original primary Gleason score. A comparison to a subset of patients treated previously with ADT was undertaken. Results: Of the 251 patients, 204 (81.3%) had evidence of recurrence on 18F-PSMA-1007 PET/CT. The detection rates were 94.0% (79/84), 90.9% (50/55), 74.5% (35/47), and 61.5% (40/65) for PSA levels of greater than or equal to 2, 1 to less than 2, 0.5 to less than 1, and 0.2 to less than 0.5 ng/mL, respectively. 18F-PSMA-1007 PET/CT revealed local recurrence in 24.7% of patients (n = 62). Lymph node metastases were present in the pelvis in 40.6% of patients (n = 102), in the retroperitoneum in 19.5% of patients (n = 49), and in supradiaphragmatic locations in 12.0% of patients (n = 30). Bone and visceral metastases were detected in 40.2% of patients (n = 101) and in 3.6% of patients (n = 9), respectively. In tumors with higher Gleason scores (≤7 vs. ≥8), detection efficacy trended higher (76.3% vs. 86.7%) but was not statistically significant (P = 0.32). However, detection efficacy was higher in patients who had received ADT (91.7% vs. 78.0%) within 6 mo before imaging (P = 0.0179). Conclusion:18F-PSMA-1007 PET/CT offers high detection rates for BCR after radical prostatectomy that are comparable to or better than those published for 68Ga-labeled PSMA ligands.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Giesel FL, Knorr K, Spohn F, et al. Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2018. PMID: 30042163. doi:10.2967/jnumed.118.212233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。